LC
IRMD icon

Lindbrook Capital’s iRadimed IRMD Stock Holding History

Lindbrook Capital’s Portfolio IRMD Stock Details IRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4
Closed -$220 – 2862
2024
Q4 		$220 Buy
+4
New +$210 ﹤0.01% 2712

Other funds holding IRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Copeland Capital Management Conshohocken, Pennsylvania $4.87B AUM 31.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Lindbrook Capital's IRMD Position: Q1 2025 in Review

Lindbrook Capital sold out of iRadimed (IRMD) in Q1 2025, closing a stake of 4 shares — an estimated $220 sold.

Lindbrook Capital first reported a position in IRMD in Q4 2024 and held it in 1 quarter. The position peaked at $220 in Q4 2024. 168 funds tracked by Wall St. Rank hold IRMD as of Q1 2025.

  • Lindbrook Capital reported no remaining iRadimed position as of Q1 2025 after selling out during the quarter.
  • Lindbrook Capital sold 4 iRadimed shares in Q1 2025, an estimated $220.
  • Lindbrook Capital first reported a position in iRadimed in Q4 2024 and held it in 1 quarter.
  • Lindbrook Capital's iRadimed position peaked at $220 in Q4 2024.
  • 168 funds tracked by Wall St. Rank held iRadimed as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.